| Health / Medical Topics |
Dendritic Cell-gp100-MART-1 Antigen Vaccine
An autologous dendritic cells vaccine with antineoplastic property. Dendritic cells harvested from cancer patients are pulsed with human gp100 melanoma antigen and MART-1 (melanoma antigen recognized by T-cells) antigen; both antigens are up-regulated in melanomas. Vaccination with this vaccine may elicit the host immune response against MART-1 or gp100 expressing cells. (NCI Thesaurus)
YOU MAY ALSO LIKE
A vaccine comprised of autologous dendritic cells pulsed with G9-209-2m peptide, a modified epitope of the gp100 melanoma-associated antigen.
A cancer vaccine consisting of dendritic cells harvested from a patient with cancer and pulsed or transduced with a peptide fragment of…
A cancer vaccine consisting of lymphocytes harvested from a patient with lung cancer and induced to become antigen-presenting cells (APCs) known as…
A vaccine made of antigens and dendritic antigen-presenting cells (APCs).
A dendritic cell neoplasm that does not fall into well-defined categories or shows hybrid features.
A vaccine composed of dendritic cells pulsed with peptide epitopes that stimulate cytotoxic T lymphocyte anti-tumor activity.
